Pregnant women may get safer HIV protection with tailored PrEP doses

NCT ID NCT06435026

Completed Prevention Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different daily doses of the HIV prevention pill PrEP in 54 pregnant women in Sub-Saharan Africa. The goal was to find the dose that gives the best protection without harming the mother or baby. Researchers measured drug levels in the blood and tracked any side effects. The results will help guide safer HIV prevention during pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) - a daily pill to prevent HIV
What this could lead to: If successful, this could lead to better HIV prevention guidelines for pregnant women, reducing mother-to-child transmission.
What could go wrong: This is a small, early-stage study (54 participants) focused on drug levels and safety, not on actual HIV prevention. Higher doses may cause more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREGNANCY PREVENTION

Contacts and locations

Locations

Bwaila District Hospital

Lilongwe, Malawi
Seke North CRS

Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.